A5021894062- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Melanoma and MAPK Pathways
- RNA modifications and cancer
- Cutaneous Melanoma Detection and Management
- Molecular Biology Techniques and Applications
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Lung Cancer Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Immunotherapy and Immune Responses
- Cancer-related molecular mechanisms research
- Chronic Myeloid Leukemia Treatments
- RNA Research and Splicing
- CRISPR and Genetic Engineering
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Educational Practices and Policies
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
Centre Hospitalier Universitaire de Nantes
2013-2023
Laboratoire de Biochimie
2023
Nantes Université
2012-2021
Inserm
2015-2021
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2016-2021
Centre d'Investigation Clinique de Nantes
2020
Centre National de la Recherche Scientifique
2009-2016
Institut de génétique et de développement de Rennes
2009-2015
Centre National pour la Recherche Scientifique et Technique (CNRST)
2015
Université de Rennes
2009-2015
// Guillaume Herbreteau 1, 2 , Audrey Vallée Anne-Chantal Knol Sandrine Théoleyre Gaelle Quéreux 2, 3, 4 Emilie Varey Amir Khammari Brigitte Dréno and Marc G. Denis 1 Laboratoire de Biochimie et Plateforme Génétique Moléculaire des Cancers, CHU Nantes, France Centre Recherche en Cancérologie Immunologie, CRCINA, INSERM U1232, 3 Service Dermatologie, d’Investigation Clinique CIC1413, Correspondence to: Denis, email:...
Progress in the liquid biopsy field, combined with development of droplet digital PCR (ddPCR), has enabled noninvasive monitoring mutations high detection accuracy. However, current assays detect a restricted number per reaction. ddPCR is recognized method for detecting alterations previously characterized tumor tissues, but its use as discovery tool when mutation unknown priori remains limited.We established 2 all genomic within KRAS exon and EGFR 19 hotspots, which are clinical importance...
Background/Objectives: Circulating tumor DNA (ctDNA) analysis is a powerful tool for non-invasive monitoring of burden and treatment response. Reliable quantification methods are critical the effective use ctDNA as biomarker. Digital PCR (dPCR) offers high sensitivity quantification, but requires prior knowledge tumor-specific genomic alterations. Next-generation sequencing (NGS) provides more comprehensive approach semi-quantitative, relying on variant allelic fraction (VAF), which can be...
Abstract Circulating tumor DNA is a promising non‐invasive tool for cancer monitoring. The main objective of our work was to investigate the relationship between mutant BRAF in plasma and clinical response. Thirty‐eight stage IV patients with V600 mutated melanoma were included prior any treatment. extracted from detected using amplification‐refractory mutation system method. Before beginning treatment, corresponding 29 38 tested samples (76.3% positive per cent agreement). We observed...
Activating mutations of the epidermal growth factor receptor (EGFR) in lung tumors are associated with a dramatic response to tyrosine kinase inhibitors. Therefore, routine analysis pathological specimens is mandatory clinical practice. We have prospectively tested from Caucasian tumor patients between January 2010 and June 2012. DNA was extracted formalin-fixed paraffin-embedded tissues following macrodissection. The p.L858R substitution assessed by allele-specific PCR exon 19 deletions...
The ability of early (first weeks treatment) ctDNA kinetics to identify primary resistance anti-PD1 immunotherapies was evaluated with a validation cohort 49 patients treated for metastatic BRAF or NRAS-mutated melanoma, alone and pooled the 53 from previously described derivation cohort. NRAS mutations were quantified on plasma DNA by digital PCR at baseline after two four treatment. interpreted according pre-established biological response criteria. A progression (bP, i.e., significant...
In September 2012, a 74-year-old nonsmoker man was admitted to our hospital with dyspnea and general health degradation. A tumor in the upper lobe of right lung, bilateral mediastinal lymphadenopathies, pleural effusion were evident on abdominal computed tomography (CT) scan (Fig. 1B). Both lung biopsies contained cells presenting p.L858R EGFR (exon 21) mutation. This alteration also detected plasma sample collected before treatment 1A). Two months after tyrosine kinase inhibitor (TKI)...
Screening for theranostic biomarkers is mandatory the therapeutic management of cutaneous melanoma. BRAF and NRAS genes must be tested in routine clinical practice. The methods used to identify these alterations sensitive detect mutant alleles a background wild type alleles, specific correct mutation. They should not require too much material, since some cases available samples are small biopsies. Finally, they also quick enough allow rapid patients. Sixty five consecutive formalin-fixed...
Targeted inactivations of RNA-binding proteins (RNA-BPs) can lead to huge phenotypical defects. These defects are due the deregulation certain mRNAs. However, we generally do not know, among hundreds mRNAs that normally controlled by one RNA-BP, which responsible for observed phenotypes. Here, designed an antisense oligonucleotide (“target protector”) masks binding site RNA-BP CUG-binding protein 1 (CUGBP1) on mRNA Suppressor Hairless [Su(H)] encodes a key player Notch signaling. We showed...
Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was determine whether the detection ctDNA, based on identification BRAF and NRAS mutations before systemic treatment initiation, associated with prognosis metastatic melanoma. In total, 68 or NRAS-mutated stage IV unresectable III cutaneous melanoma patients were included tested for presence in circulating using Cobas BRAF/NRAS Mutation Test (Roche). expected mutation detected plasma 34/68 (50%...
Detection of genomic rearrangements, like anaplastic lymphoma kinase (ALK) fusions, is a pivotal requirement in non-small cell lung cancer (NSCLC) for the initiation targeted treatment. While tissue testing remains gold standard, detection these alterations using liquid biopsies an unmet need. To enable ALK rearrangements from circulating-free RNA (cfRNA) NSCLC patients, we have evaluated novel reverse transcription PCR (RT-PCR) based assay.Sixty-six patients with advanced stage were...
Several different mRNAs can be produced from a given pre-mRNA by regulated alternative splicing, or as the result of deregulations that may lead to pathological states. Analysing splicing patterns is therefore importance describe and understand developmental programs, cellular responses internal external cues, human diseases. We here method, Pyrosequencing Analysis Splicing Patterns (PASP), combines RT–PCR pyrosequencing PCR products. demonstrated that: (i) Ratios two pure RNAs mixed in...
Fixed tissues are the standard samples used in routine practice for molecular testing. But sometimes lacking or difficult to obtain. In these cases, circulating tumor DNA released from cells can be as an alternative source of DNA. We present case a 63-year-old Caucasian woman with metastatic melanoma and very poor performance status. A plasma sample was tested BRAF p.V600E mutation detected. Based on this result, treatment combining inhibitor MEK immediately started. This patient achieved...